Podrobno

The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes
ID Battelino, Tadej (Avtor), et al.

.pdfPDF - Predstavitvena datoteka, prenos (872,57 KB)
MD5: FEAB3D31FF6B35CFFA0CB943E22D3230
URLURL - Izvorni URL, za dostop obiščite https://www.sciencedirect.com/science/article/pii/S0168822725001251 Povezava se odpre v novem oknu

Izvleček
A global trend towards increased obesity, intermediate hyperglycemia (previously termed prediabetes) and type 2 diabetes, has prompted a range of international initiatives to proactively raise awareness and provide action-driven recommendations to prevent and manage these linked disease states. One approach, that has shown success in managing people already diagnosed with type 2 diabetes mellitus, is to use continuous glucose monitoring (CGM) devices to help them manage their chronic condition through understanding and treating their daily glucose fluctuations, in assocation with glucose-lowering medications, including insulin. However, much of the burden of type 2 diabetes mellitus is founded in the delayed detection both of type 2 diabetes mellitus itself, and the intermediate hyperglycemia that precedes it. In this review, we provide evidence that using CGM technology in people at-risk of intermediate hyperglycemia or type 2 diabetes mellitus can significantly improve the rate and timing of detection of dysglycemia. Earlier detection allows intervention, including through continued use of CGM to guide changes to diet and lifestyle, that can delay or prevent harmful progression of early dysglycemia. Although further research is needed to fully understand the cost-effectiveness of this intervention in people at-risk or with early dysglycemia, the proposition for use of CGM technology is clear.

Jezik:Angleški jezik
Ključne besede:continuous glucose monitoring, consensus statements, intermediate hyperglycemia, obesity, prediabetes, type 2 diabetes
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2025
Št. strani:12 str.
Številčenje:Vol. 223, art. 112111
PID:20.500.12556/RUL-181976 Povezava se odpre v novem oknu
UDK:616.379
ISSN pri članku:1872-8227
DOI:10.1016/j.diabres.2025.112111 Povezava se odpre v novem oknu
COBISS.SI-ID:250818563 Povezava se odpre v novem oknu
Datum objave v RUL:21.04.2026
Število ogledov:313
Število prenosov:167
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Diabetes research and clinical practice
Založnik:Elsevier
ISSN:1872-8227
COBISS.SI-ID:23224837 Povezava se odpre v novem oknu

Licence

Licenca:CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
Opis:Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.

Projekti

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0343
Naslov:Etiologija, zgodnje odkrivanje in zdravljenje bolezni pri otrocih in mladostnikih

Financer:UKRI - UK Research and Innovation
Program financ.:MRC
Številka projekta:MR/W030004/1
Naslov:Using mesenchymal stromal cell secretory products to improve human islet transplantation

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj